TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Maximum observed plasma concentration (Cmax) for Famitinib after Single dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUC0-t) for Famitinib after Single dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUC0-∞) for Famitinib after Single dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hospitalization due to delayed bleeding complication
Endpoint domain: Adverse events/effects
Primary endpoint: transfusion due to delayed bleeding complication
Endpoint domain: Adverse events/effects
Primary endpoint: repeat endoscopy due to delayed bleeding complication
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of anti-CD19 CAR T cell therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Time from first period of unexpected physiological instability to set of observations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean pain score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Proportion of pregnancy-related AESI and SAE from vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: MRI lesion magnetization transfer ratio (MTR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time to any Treatment Change
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Participants Who Discontinued the Vedolizumab Treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Efficacy of MP as a predictor of weaning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Had Undetectable SARS-CoV-2 and Developed COVID-19
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants With ≥1 Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Discontinuing From Study Therapy Due to AE
Endpoint domain: Adverse events/effects
Primary endpoint: Evaluation of attachment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Evaluation of family satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage changes of alkaline phosphatase (ALP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: expression of CD34
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: expression of CXCR4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of recurrent bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total number of antibiotics courses prescribed for URTIs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of antibiotics prescription dispensed for an inappropriate use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: WOMAC pain scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-operative vertebral re-fracture within 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Quality of life associated with restless legs syndrome
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of sleep associated with restless legs syndrome
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: proportion of successful wound closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in rubella antibody level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Vape Pen Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prescription Opioid Use for Acute Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early complete metabolic response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation between PetCO2, PaCO2, and PtcCO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Physical performance change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: miRNA levels in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freestyle Time Trial (TT) Swimming Performance Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood Lactate Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Borg Fatigue Scale
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in GMFM-88 D Item
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in GMFM-88 E Item
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical remission rate (CRR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pathological remission rate (PRR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PVC burden reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of patients where substance use was addressed during a MH visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients diagnosed with OUD or AUD who initiated pharmacotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Three-month retention in MH services for new patients
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Grief measured by Texas Revised Inventory of Grief
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Body fat mass measurement accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in NeuroQOL lower extremity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Hot Flash related Interference Scale (HFRDIS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: FATIGUE SEVERITY SCALE
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: DASS-21 (Depression, Anxiety and stress scale 21-item)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: EAT density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Monocyte count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Attentional Control
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Decentering
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Reappraisal
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Valued Living/Action
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in Clarity of Approach-Avoidance Motivation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Presence vs. absence of clinically significant prostate cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in SCI-PANSS Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean daytime and nocturnal glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time in range daytime (TIRd) 3.9-10.0 mmol/l
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time in range night-time (TIRn) 3.9-10 mmol/l
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-Inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants discontinuing study treatment due to an AE
Endpoint domain: Adverse events/effects
Primary endpoint: Global Quality of Life scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Caregiver feeling
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Occurrence of grade 4 hematologic AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Balance in children with cerebral palsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of DaRT treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Intracranial lesion tumor-to-background ratio (TBRmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of accurate prediction of presence of tumor (Population 1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of radiological read responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall performance in wound healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Overall safety in wound healing
Endpoint domain: Adverse events/effects
Primary endpoint: Cycle 1 Area Under The Curve From 0-3 Weeks (AUC 0-3wks) of Pembrolizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cycle 6 Model-Based Minimal Concentration (Ctrough) of Pembrolizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with supraventricular tachycardia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: AUC of elinzanetant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IPOS score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Contra-lateral pelvic drop angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for bupivacaine for epidural analgesia
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: COVID-19 Persistent Symptom Questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: survival after diagnosis of spinal metastasis
Endpoint domain: Mortality/survival
Primary endpoint: Rape myth acceptance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Monitoring disease course or vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Intraepidermal Nerve Fiber Density on Lesional Skin at Week 17
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Participants With Change From Baseline in Nerve Fiber Branching on Lesional Skin at Week 17
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Gastrointestinal symptoms intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of AEs related to an allogeneic CAR-T therapy leading to death
Endpoint domain: Adverse events/effects
Primary endpoint: Dorsal Angulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metacarpal Shortening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pill burden for abortive treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Safety and tolerability of RN0361
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Healthcare related Quality of Life (EQ5D5L)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Healthcare resource use during waiting list
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of participants achieving ≥ 5% loss in body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cortical Excitability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specific Peak Amplitudes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GMFP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Verbal Numerical Pain Rating Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arm Function as Assessed by the Fugl-Meyer Score of Upper Extremity Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in patient-reported total irritation score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean change in Monthly Migraine Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional dyspepsia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of patients who prematurely discontinue treatment due to intolerability or adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of adverse events (AEs), severe adverse events (SAEs), adverse event of special interest (AESI) and suspected unexpected serious adverse reactions (SUSARs)
Endpoint domain: Adverse events/effects
Primary endpoint: 30 day Post-operative complications
Endpoint domain: Adverse events/effects
Primary endpoint: rate of major malformations in fetus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: rate of major malformations in newborns
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Change in urinary 11-dehydro-thromboxane B2 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in serum thromboxane B2 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Olfactory threshold changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Olfactory identification score changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Newborn Comfort Behavior Scale (NEAS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Perspectives on reproductive decision-making
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Postoperative self-care ability scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: State anxiety scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of family physicians providing family planning services
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Scale for Contraversive Pushing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Burke Lateropulsion Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NAD+/NADH ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Effectiveness of TachoSil
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Safety of TachoSil
Endpoint domain: Adverse events/effects
Primary endpoint: Two Point Discrimination Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Heart-rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Correlation of ME&MG test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaccine hesitancy at pre-test
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Vaccine hesitancy at post-intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Vaccine hesitancy at three months follow-up
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Vaccine hesitancy at six months follow-up
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient Pain/Discomfort (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in perinatal best practices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in perinatal mental health protocols
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Carbidopa/levodopa serum level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of apnoea tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Baseline arterial carbon dioxide (CO2) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Steady-State Visually Evoked Response (SSVEP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of radiation-induced dermatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Analog visual scale
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in ANMS GCSI-DD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Strategies description
Endpoint domain: null
Endpoint subdomain: null
Primary endpoint: Clinical measurement of ET severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healing of mucosal lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient-based lateral epicondylitis assessment questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: 30-day complication rates
Endpoint domain: Adverse events/effects
Primary endpoint: Numerical pain scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor Overall Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: hip flexion/extension angle at the initial touchdown moment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: knee flexion/extension angle at the initial touchdown moment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ankle dorsiflexion/plantarflexion angle at the initial touchdown moment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal Left Atrial (LA) longitudinal strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma EBV DNA Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Behavioral Rating Inventory Of Executive Function (BRIEF)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Participant improvement as measured by participant distress screening tool
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Quality of life as measured by PHQ-9 Patient Depression Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Highest absolute change of T from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in vegetable and fruit intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment separation in energy adequacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Soleus H-Reflex size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Vaginal Deliveries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Intended Performance of Optimum TAV - mean aortic valve gradient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Intended Performance of Optimum TAV - peak aortic valve velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Satisfaction With Medication
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to Alleviation or Improvement of COVID-19 Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Intensity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: NeuroQoL Upper Extremity Function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Participant Drop-out rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Conditioned Pain Modulation Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Strains detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Achievement of cDAPSA low disease activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Investigator Global Assessment of Psoriasis of Clear or Almost Clear
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success/failure of LMA insertion on the first attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean Hemoglobin (Hb) change from baseline to average levels from Week 28 to Week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of subjects who achieve a Hb response during the first 24 weeks of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: The incidence of cardiovascular and cerebrovascular events within 52 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes